PEG-MGF

PEG-MGF is a pegylated form of mechano growth factor, a peptide corresponding to the unique C-terminal E-domain of an alternatively spliced insulin-like-growth-factor-1 variant (IGF-1Ec) expressed in mechanically loaded tissue. Investigators study it as a structurally defined research material in tissue-repair and satellite-cell research models, where the polyethylene-glycol conjugation is used to extend the short native stability of the E-domain peptide for experimental work. The peer-reviewed literature catalogs MGF and its E-domain peptide in muscle-repair, myoblast-proliferation, and regeneration-signaling research. Supplied for laboratory characterization and in-vitro signaling studies only. For research use only; not for human consumption, medical use, or veterinary application. Researchers should consult primary literature for context-specific experimental conditions.

PEG-MGF couples the C-terminal E-domain peptide of the mechano-growth-factor splice variant to a polyethylene-glycol moiety. The literature documents that the native E-domain peptide acts distinctly from mature IGF-1 — it is described as engaging myoblast and satellite-cell proliferation signaling separately from the IGF-1-receptor-mediated differentiation pathway of the mature growth factor. PEGylation is documented as a general strategy for extending the plasma and buffer stability of small peptides by increasing hydrodynamic radius and reducing proteolytic accessibility, without altering the peptide’s primary sequence. Pharmacokinetic descriptors documented in published investigations therefore emphasize extended functional residence relative to the unmodified E-domain peptide. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Identity is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis, with the PEG-conjugation profile reported categorically.

Experimental domains documented in the published literature include myoblast and satellite-cell proliferation assays, muscle tissue-repair and regeneration-signaling research, comparative structure-activity work distinguishing the MGF E-domain peptide from mature IGF-1, and stability-profiling studies comparing pegylated and unmodified peptide forms. Investigators use PEG-MGF research materials to study the E-domain signaling arm of the mechano-growth-factor splice variant under experimental conditions requiring extended peptide stability. Use in laboratory research extends to mechanism-elucidation paradigms where the pegylated peptide serves as a defined MGF-E-domain reference. The reference material is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary use.

Each lot is characterized by reverse-phase and size-exclusion HPLC for chromatographic purity and PEG-conjugation homogeneity, and by mass spectrometry for confirmation of the peptide core; because polyethylene-glycol conjugation produces a mass distribution rather than a single molecular ion, the PEG profile is reported categorically alongside the confirmed peptide-core mass. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot. Peptide content is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized pegylated peptide should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Although PEGylation improves handling stability relative to the unmodified peptide, repeated freeze-thaw cycles of reconstituted material should still be avoided — single-use aliquots are preferred where peptide integrity is assay-critical. These handling parameters reflect general best-practice for pegylated peptide reference materials and do not constitute preparation guidance for human or veterinary use.